Condition: Coronary Artery Disease · Ischemic Mitral Regurgitation · Angiotensin Receptor/Neprilysin Inhibitor · Sponsor: China National Center for Cardiovascular Diseases
This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.
This description comes directly from the study's public registry record.
Lianxin Chen, M.D. · 010-88322265 · chenlianx1@163.com
Always discuss trial participation with your own doctor first.
| China National Center for Cardiovascular Diseases | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06917664